CA SR88

Urges the President and Congress to redirect United States medical supply chains away from China and create incentives for increased domestic pharmaceutical production

Highlights that the number of registered pharmaceutical ingredient facilities in China more than doubled between 2010 and 2019

Notes that California spent nearly $1 billion on medical masks and N95 respirators from China during the COVID-19 crisis

Identifies critical dependency on Chinese suppliers for 97 percent of antibiotics, 95 percent of ibuprofen, 90 percent of vitamin C, and significant portions of other essential medications

References federal legislation proposal called the Protecting our Pharmaceutical Supply Chain from China Act of 2020 that would establish pharmaceutical registries and restrict government purchases of products with Chinese-made active pharmaceutical ingredients